CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT07335497. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with locally advanced or metastatic solid tumors.
Study identification
- NCT ID
- NCT07335497
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 540 participants
Conditions and interventions
Conditions
Interventions
- CR-001 Drug
- Paclitaxel Drug
- trifluridine and tipiracil Drug
- Pemetrexed Drug
- Carboplatin Drug
- Oxaliplatin Drug
- Gemcitabin Drug
- Cisplatin Drug
- Capecitabine Drug
- FOLFOX Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 17, 2026 (Actual)
- Primary completion
- Feb 2029 (Estimated)
- Completion
- Feb 2029 (Estimated)
- Last update posted
- Oct 20, 2026
2026 – 2029
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Study Site | Birmingham | Alabama | 35294 | Recruiting |
| Clinical Study Site | Los Angeles | California | 90033 | Recruiting |
| Clinical Study Site | Denver | Colorado | 80218 | Recruiting |
| Clinical Study Site | Washington D.C. | District of Columbia | 20009 | Recruiting |
| Clinical Study Site | Orlando | Florida | 32827 | Recruiting |
| Clinical Study Site | Sarasota | Florida | 34236 | Recruiting |
| Clinical Study Site | Detroit | Michigan | 48201 | Recruiting |
| Clinical Study Site | Grand Rapids | Michigan | 49546 | Recruiting |
| Clinical Study Site | New York | New York | 10029 | Recruiting |
| Clinical Study Site | Columbus | Ohio | 43210 | Recruiting |
| Clinical Study Site | Pittsburgh | Pennsylvania | 15232 | Recruiting |
| Clinical Study Site | Nashville | Tennessee | 37203 | Recruiting |
| Clinical Study Site | Dallas | Texas | 75230 | Recruiting |
| Clinical Study Site | San Antonio | Texas | 78229 | Recruiting |
| Clinical Study Site | West Valley City | Utah | 84119 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07335497, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 20, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07335497 live on ClinicalTrials.gov.